115 related articles for article (PubMed ID: 19480557)
1. Studies on the pharmacokinetics and metabolism of a gamma-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction.
Zheng M; Wang J; Lubinski J; Flint OP; Krishna R; Yao M; Pursley JM; Thakur A; Boulton DW; Santone KS; Barten DM; Anderson JJ; Felsenstein KM; Hansel SB
Xenobiotica; 2009 Jul; 39(7):544-55. PubMed ID: 19480557
[TBL] [Abstract][Full Text] [Related]
2. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
Huwyler J; Wright MB; Gutmann H; Drewe J
Curr Drug Metab; 2006 Feb; 7(2):119-26. PubMed ID: 16472102
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor.
Zhang D; Hanson R; Roongta V; Dischino DD; Gao Q; Sloan CP; Polson C; Keavy D; Zheng M; Mitroka J; Yeola S
Curr Drug Metab; 2006 Dec; 7(8):883-96. PubMed ID: 17168689
[TBL] [Abstract][Full Text] [Related]
4. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.
Sahi J; Milad MA; Zheng X; Rose KA; Wang H; Stilgenbauer L; Gilbert D; Jolley S; Stern RH; LeCluyse EL
J Pharmacol Exp Ther; 2003 Sep; 306(3):1027-34. PubMed ID: 12766253
[TBL] [Abstract][Full Text] [Related]
5. Endosulfan induces CYP2B6 and CYP3A4 by activating the pregnane X receptor.
Casabar RC; Das PC; Dekrey GK; Gardiner CS; Cao Y; Rose RL; Wallace AD
Toxicol Appl Pharmacol; 2010 Jun; 245(3):335-43. PubMed ID: 20361990
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG
Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149
[TBL] [Abstract][Full Text] [Related]
7. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog.
Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH
Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240
[TBL] [Abstract][Full Text] [Related]
9. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.
Hariparsad N; Nallani SC; Sane RS; Buckley DJ; Buckley AR; Desai PB
J Clin Pharmacol; 2004 Nov; 44(11):1273-81. PubMed ID: 15496645
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
[TBL] [Abstract][Full Text] [Related]
11. The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's disease.
Meunier J; Villard V; Givalois L; Maurice T
Eur J Pharmacol; 2013 Jan; 698(1-3):193-9. PubMed ID: 23123349
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Kim S; Dinchuk JE; Anthony MN; Orcutt T; Zoeckler ME; Sauer MB; Mosure KW; Vuppugalla R; Grace JE; Simmermacher J; Dulac HA; Pizzano J; Sinz M
Drug Metab Dispos; 2010 Jan; 38(1):16-24. PubMed ID: 19833845
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.
Cerveny L; Svecova L; Anzenbacherova E; Vrzal R; Staud F; Dvorak Z; Ulrichova J; Anzenbacher P; Pavek P
Drug Metab Dispos; 2007 Jul; 35(7):1032-41. PubMed ID: 17392393
[TBL] [Abstract][Full Text] [Related]
15. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes.
Drocourt L; Pascussi JM; Assenat E; Fabre JM; Maurel P; Vilarem MJ
Drug Metab Dispos; 2001 Oct; 29(10):1325-31. PubMed ID: 11560876
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
17. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression.
Li T; Chiang JY
Drug Metab Dispos; 2006 May; 34(5):756-64. PubMed ID: 16455805
[TBL] [Abstract][Full Text] [Related]
18. Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor.
Yang J; Yan B
Toxicol Sci; 2007 Jan; 95(1):13-22. PubMed ID: 17003103
[TBL] [Abstract][Full Text] [Related]
19. PXR/CYP3A4-humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein.
Holmstock N; Gonzalez FJ; Baes M; Annaert P; Augustijns P
Mol Pharm; 2013 Mar; 10(3):1056-62. PubMed ID: 23360470
[TBL] [Abstract][Full Text] [Related]
20. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
